Literature DB >> 15711958

Population-based study of bronchopulmonary dysplasia in very low birth weight infants in Switzerland.

Juliane Hentschel1, Thomas M Berger, Alois Tschopp, Martina Müller, Mark Adams, Hans-Ulrich Bucher.   

Abstract

UNLABELLED: In Switzerland, data are collected prospectively by collaborators from all nine neonatal intensive care units and their affiliated paediatric units caring for neonates, to determine survival and (pulmonary) outcome of infants with birth weights ranging from 501 to 1500 g. To assess the pulmonary outcome of very low birth weight (VLBW) infants in Switzerland in 1996 and 2000, factors associated with bronchopulmonary dysplasia (BPD) were identified and compared with pulmonary outcomes from the Vermont Oxford Network data. BPD was defined as a requirement for supplemental oxygen at 36 weeks postmenstrual age. Complete data were available for 600 and 636 VLBW infants in 1996 and in 2000, respectively. Mortality rates in Switzerland were significantly higher (1996: 19.2%, 2000: 20.8%) than in the Vermont Oxford Network (1996: 14%, 2000: 14%). Expressed as percentage of infants still hospitalised at 36 weeks postmenstrual age, 16.7% and 13.2% of Swiss VLBW infants were diagnosed with BPD in 1996 and 2000, respectively. These rates were significantly lower than in the Vermont Oxford Network (1996: 28%, 2000: 35%). Infants exposed to factors previously shown to be associated with BPD were investigated: in Switzerland, infants with a history of surfactant replacement therapy and/or mechanical ventilation had a significantly higher rate of BPD in both cohorts. Infants with postnatal transport, sepsis proven by positive blood culture and patent ductus arteriosus had a higher BPD rate only in the 1996 cohort. Between 1996 and 2000, mortality rates and incidence of BPD in VLBW infants remained unchanged in Switzerland. BPD rates in Switzerland are lower than those found in the Vermont Oxford Network whereas a mortality rate comparison displays an inverted picture. We suspect that these effects are interrelated and may be due in part to a selective approach of Swiss neonatologists to resuscitation of infants in the smallest birth weight stratum.
CONCLUSION: The factors listed above have apparently become less important in the context of bronchopulmonary dysplasia and other influences, including prenatal conditions, will need to be investigated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15711958     DOI: 10.1007/s00431-005-1623-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  21 in total

1.  Impact of antenatal corticosteroid therapy in very low birth weight infants on chronic lung disease and other morbidities of prematurity.

Authors:  L R Wells; L A Papile; M O Gardner; C R Hartenberger; L Merker
Journal:  J Perinatol       Date:  1999-12       Impact factor: 2.521

2.  Factors affecting the incidence of chronic lung disease of prematurity in 1987, 1992, and 1997.

Authors:  B N Manktelow; E S Draper; S Annamalai; D Field
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-07       Impact factor: 5.747

3.  Improved outcomes for very low birthweight infants: evidence from New Zealand national population based data.

Authors:  B A Darlow; A E Cust; D A Donoghue
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-01       Impact factor: 5.747

4.  Acute neonatal respiratory distress in Italy: a one-year prospective study. Italian Group of Neonatal Pneumology.

Authors:  F F Rubaltelli; C Dani; M F Reali; G Bertini; L Wiechmann; M Tangucci; A Spagnolo
Journal:  Acta Paediatr       Date:  1998-12       Impact factor: 2.299

5.  Inflammatory mediators and bronchopulmonary dysplasia.

Authors:  P Groneck; C P Speer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-07       Impact factor: 5.747

6.  Annual summary of vital statistics: 2000.

Authors:  D L Hoyert; M A Freedman; D M Strobino; B Guyer
Journal:  Pediatrics       Date:  2001-12       Impact factor: 7.124

7.  Population-based study of chronic lung disease in very low birth weight infants in North Carolina in 1994 with comparisons with 1984. The North Carolina Neonatologists Association.

Authors:  T E Young; L S Kruyer; D D Marshall; C L Bose
Journal:  Pediatrics       Date:  1999-08       Impact factor: 7.124

8.  Registration artifacts in international comparisons of infant mortality.

Authors:  Michael S Kramer; Robert W Platt; Hong Yang; Bengt Haglund; Sven Cnattingius; Per Bergsjo
Journal:  Paediatr Perinat Epidemiol       Date:  2002-01       Impact factor: 3.980

9.  Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease.

Authors:  M A Rojas; A Gonzalez; E Bancalari; N Claure; C Poole; G Silva-Neto
Journal:  J Pediatr       Date:  1995-04       Impact factor: 4.406

10.  Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994.

Authors:  D K Stevenson; L L Wright; J A Lemons; W Oh; S B Korones; L A Papile; C R Bauer; B J Stoll; J E Tyson; S Shankaran; A A Fanaroff; E F Donovan; R A Ehrenkranz; J Verter
Journal:  Am J Obstet Gynecol       Date:  1998-12       Impact factor: 8.661

View more
  10 in total

Review 1.  Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia.

Authors:  Rita M Ryan; Qadeer Ahmed; Satyan Lakshminrusimha
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

2.  Neonatal outcomes of very preterm infants admitted to a tertiary center in Lithuania between the years 2003 and 2005.

Authors:  Rita Jakuskiene; Brigitte Vollmer; Viktoras Saferis; Dalia Daugeliene
Journal:  Eur J Pediatr       Date:  2011-03-15       Impact factor: 3.183

3.  Pharyngo-esophageal complications of Ryle tube insertion in neonates: management and fate.

Authors:  Ahmed M Refaat; Mohamed N Kotby
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-06-29       Impact factor: 2.503

4.  Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial.

Authors:  Wes Onland; Martin Offringa; Filip Cools; Anne P De Jaegere; Karin Rademaker; Henry Blom; Eric Cavatorta; Anne Debeer; Peter H Dijk; Arno F van Heijst; Boris W Kramer; Andre A Kroon; Thilo Mohns; Henrica L van Straaten; Arjan B te Pas; Claire Theyskens; Mirjam M van Weissenbruch; Anton H van Kaam
Journal:  BMC Pediatr       Date:  2011-11-09       Impact factor: 2.125

5.  Pulmonary effects of neonatal hydrocortisone treatment in ventilator-dependent preterm infants.

Authors:  Sandra E A de Jong; Floris Groenendaal; Frank van Bel; Karin J Rademaker
Journal:  Int J Pediatr       Date:  2011-12-20

Review 6.  Patent ductus arteriosus ligation and adverse outcomes: causality or bias?

Authors:  Dany E Weisz; Patrick J McNamara
Journal:  J Clin Neonatol       Date:  2014-04

7.  Contributing death factors in very low-birth-weight infants by path method analysis.

Authors:  Morteza Ghojazadeh; Atefeh Velayati; Fatemeh Mallah; Saber Azami-Aghdash; Keyvan Mirnia; Reza Piri; Mohammad Naghavi-Behzad
Journal:  Niger Med J       Date:  2014-09

8.  Reduced internalization of TNF-ɑ/TNFR1 down-regulates caspase dependent phagocytosis induced cell death (PICD) in neonatal monocytes.

Authors:  Stephan Dreschers; Christian Gille; Martin Haas; Florence Seubert; Christopher Platen; Thorsten W Orlikowsky
Journal:  PLoS One       Date:  2017-08-09       Impact factor: 3.240

9.  Amphiregulin Regulates Phagocytosis-Induced Cell Death in Monocytes via EGFR and Matrix Metalloproteinases.

Authors:  Christopher Platen; Stephan Dreschers; Lucy Kathleen Reiss; Jessica Wappler; Thorsten W Orlikowsky
Journal:  Mediators Inflamm       Date:  2018-11-04       Impact factor: 4.711

10.  Amphiregulin Regulates Phagocytosis-Induced Cell Death in Monocytes via EGFR and the Bcl-2 Protein Family.

Authors:  Christopher Platen; Stephan Dreschers; Jessica Wappler; Andreas Ludwig; Stefan Düsterhöft; Lucy Kathleen Reiss; Thorsten W Orlikowsky
Journal:  Mediators Inflamm       Date:  2019-11-03       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.